Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transtec (buprenorphine) as first-line opioid for cancer pain during chemotherapy
2006-001679-39Phase 4Completed
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of buprenorphine in cancer pain, Nonhematologic neoplasms and cancer, sponsored by Policlinico Gemelli. Primary endpoint: Pain-free survival at six months. Started Dec 2006; status: completed.
02
Drugs
buprenorphine
03
Conditions
cancer painNonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2006-001679-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001679-39.